Skip to main content

Advertisement

Table 6 Dose and clinical outcome in patients with VL according to their immunological status

From: Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned?

LAB dosea (mg/kg)VL treated (n = 108)Relapses (n = 14, 13.0%)
IC-VLb818 (9.9%)
1521 (50.0%)
1853 (60.0%)
2163 LAB + 2 ABCL3 (4.6%)
305 LAB + 1 ABCL1 (16.7%)c
HIV-VL113 (27.3%)
2111 (100%)d
3042 (50.0%)e
4060
IS-VL163 (18.8%)
213 LAB + 1 ABCL1 (25.0%)f
3041 (25.0%)c
4081 (12.5%)
  1. aUsual LAB standard dose (see text): IC-VL 18–21 mg/kg; HIV-VL 30–40 mg/kg; IS-VL 21–40 mg/kg
  2. b3 IC-VL patients with solid neoplasms were treated with 21, 30 and 40 mg/dl each, with no relapses
  3. cRelapsed and died during retreatment
  4. dThis patient was clinically cured after treatment but voluntarily stopped secondary prophylaxis and relapsed
  5. eOne patient was clinically cured after treatment but voluntarily stopped secondary prophylaxis and relapsed
  6. fLack of initial response, cured after retreatment
  7. Abbreviations: LAB, liposomal B amphotericin; ABLC, amphotericin B lipid complex; IC-VL, visceral leishmaniasis in immunocompetent patients; HIV-VL, visceral leishmaniasis in patients with HIV; IS-VL, visceral leishmaniasis in immunosuppressed patients (receiving steroids, methotrexate, anti-TNF)